Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.
van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Hagenbeek A. van Oers MH, et al. Among authors: van t veer m, van glabbeke m. J Clin Oncol. 2010 Jun 10;28(17):2853-8. doi: 10.1200/JCO.2009.26.5827. Epub 2010 May 3. J Clin Oncol. 2010. PMID: 20439641 Free PMC article. Clinical Trial.
Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial--Intergroup Collaborative Study.
Van Oers MH, Hagenbeek A, Van Glabbeke M, Teodorovic I. Van Oers MH, et al. Among authors: van glabbeke m. Ann Hematol. 2002 Oct;81(10):553-7. doi: 10.1007/s00277-002-0548-2. Epub 2002 Oct 17. Ann Hematol. 2002. PMID: 12424535 Clinical Trial. No abstract available.
BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study.
van Oers MH, Tönnissen E, Van Glabbeke M, Giurgea L, Jansen JH, Klasa R, Marcus RE, Wolf M, Kimby E, Vranovsky A, Holte H, Hagenbeek A, van der Reijden BA. van Oers MH, et al. Among authors: van der reijden ba, van glabbeke m. J Clin Oncol. 2010 May 1;28(13):2246-52. doi: 10.1200/JCO.2009.25.0852. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368567 Clinical Trial.
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial.
Vellenga E, van Putten WL, van 't Veer MB, Zijlstra JM, Fibbe WE, van Oers MH, Verdonck LF, Wijermans PW, van Imhoff GW, Lugtenburg PJ, Huijgens PC. Vellenga E, et al. Among authors: van putten wl, van oers mh, van t veer mb, van imhoff gw. Blood. 2008 Jan 15;111(2):537-43. doi: 10.1182/blood-2007-08-108415. Epub 2007 Oct 30. Blood. 2008. PMID: 17971487 Free article. Clinical Trial.
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Gonzalez Diaz M, Petrini M, Sebban C, Zinzani PL, van Oers MH, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A. Morschhauser F, et al. Among authors: van oers mh, van hoof a, van putten w. J Clin Oncol. 2008 Nov 10;26(32):5156-64. doi: 10.1200/JCO.2008.17.2015. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854568 Clinical Trial.
Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis.
Vojdeman FJ, Jurlander J, van't Veer M, Itälä-Remes M, Kimby E, Tjønnfjord GE, Walewski J, Kozák T, Polliack A, Montagna M, Regazzi M, Kirkby N, van Oers M, Geisler CH. Vojdeman FJ, et al. Leuk Lymphoma. 2013 Apr;54(4):790-3. doi: 10.3109/10428194.2012.720373. Epub 2013 Jan 4. Leuk Lymphoma. 2013. PMID: 23025267
Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.
Geisler CH, van T' Veer MB, Jurlander J, Walewski J, Tjønnfjord G, Itälä Remes M, Kimby E, Kozak T, Polliack A, Wu KL, Wittebol S, Abrahamse-Testroote MC, Doorduijn J, Ghidey Alemayehu W, van Oers MH. Geisler CH, et al. Among authors: van oers mh, van t veer mb. Blood. 2014 May 22;123(21):3255-62. doi: 10.1182/blood-2014-01-547737. Epub 2014 Apr 15. Blood. 2014. PMID: 24735962 Free article. Clinical Trial.
Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.
van Imhoff GW, van der Holt B, MacKenzie MA, Ossenkoppele GJ, Wijermans PW, Kramer MH, van 't Veer MB, Schouten HC, van Marwijk Kooy M, van Oers MH, Raemaekers JM, Sonneveld P, Meulendijks LA, Kluin PM, Kluin-Nelemans HC, Verdonck LF; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). van Imhoff GW, et al. Among authors: van marwijk kooy m, van oers mh, van t veer mb, van der holt b. Leukemia. 2005 Jun;19(6):945-52. doi: 10.1038/sj.leu.2403733. Leukemia. 2005. PMID: 15800666 Clinical Trial.
CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
Doorduijn JK, van der Holt B, van Imhoff GW, van der Hem KG, Kramer MH, van Oers MH, Ossenkoppele GJ, Schaafsma MR, Verdonck LF, Verhoef GE, Steijaert MM, Buijt I, Uyl-de Groot CA, van Agthoven M, Mulder AH, Sonneveld P. Doorduijn JK, et al. Among authors: van oers mh, van agthoven m, van der hem kg, van der holt b, van imhoff gw. J Clin Oncol. 2003 Aug 15;21(16):3041-50. doi: 10.1200/JCO.2003.01.076. J Clin Oncol. 2003. PMID: 12915593 Clinical Trial.
225 results